Charlee N.
- Country
- France
- Department
- Onco-Dermatology
Research Overview
- Pharmacokinetics Study Comparing GME751 and US/EU-Approved Pembrolizumab in Stage II and III Melanoma Patients Requiring Adjuvant Therapy
- Phase 3 Randomized Study of IO102-IO103 and Pembrolizumab Versus Pembrolizumab Monotherapy in Untreated Unresectable or Metastatic Melanoma
- Phase 2 Randomized Controlled Study of Cemiplimab Monotherapy and Cemiplimab Plus Vusolimogene Oderparepvec in Advanced Cutaneous Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 43 of 138 partner sites.
Specializations
Melanoma Research
The investigator specializes in advanced melanoma treatment and demonstrates particular focus on resectable and metastatic melanoma cases. Their research encompasses both early-stage and advanced disease management.
- Stage IIB/C melanoma management
- Neoadjuvant therapy approaches
- Unresectable melanoma treatment
The investigator explores novel therapeutic combinations and immunotherapy applications in melanoma care.
Skin Cancer Therapeutics
Expertise extends to various forms of cutaneous malignancies, with particular emphasis on squamous cell carcinoma treatment strategies.
- Advanced cutaneous squamous cell carcinoma
- Metastatic skin cancer management
- Novel therapeutic approaches
The investigator focuses on developing treatment protocols for both localized and systemic disease.
Immunotherapy Innovation
The investigator's work centers on innovative immunotherapy applications in skin cancer treatment, including combination therapy approaches.
- Monoclonal antibody therapeutics
- Combination immunotherapy strategies
- Biosimilar development
Research includes evaluation of novel immunotherapy agents and therapeutic combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.